Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells

Código QR

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells

Aims: The selective molecules for targeted therapy of triple-negative breast cancer (TNBC) are limited. Several kinases play pivotal roles in cancer development and malignancy. The study aims to determine if any kinases confer to malignancy of TNBC cells, which could serve as a theranostic target fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chia-Che Chang, Chien-Chih Chiu, Pei-Feng Liu, Chih-Hsuan Wu, Yen-Chiang Tseng, Cheng-Hsin Lee, Chih-Wen Shu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	kinome siRNA screening DYRK1B prognosis triple-negative breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2540cff0fcd14bddb898526a1af215ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abdulwahab Abuderman, et al.
Publicado: (2020)

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
por: Ilie SM, et al.
Publicado: (2018)

Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery
por: Ngamcherdtrakul W, et al.
Publicado: (2018)

Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs
por: Javad Khanali, et al.
Publicado: (2021)

DYRK1A Overexpression in Mice Downregulates the Gonadotropic Axis and Disturbs Early Stages of Spermatogenesis
por: Rodolphe Dard, et al.
Publicado: (2021)

Effects of c-FLIPL Knockdown in Cervical Uterine Carcinoma Cell Lines
por: Ili,Carmen G, et al.
Publicado: (2015)

Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer
por: Zhang W, et al.
Publicado: (2019)

Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect
por: Chen M, et al.
Publicado: (2019)

GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers
por: Xu WW, et al.
Publicado: (2017)

Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey
por: Saliha Karagöz Eren, et al.
Publicado: (2021)

The Potential Prognostic Role of Oligosaccharide-Binding Fold-Containing Protein 2A (OBFC2A) in Triple-Negative Breast Cancer
por: Qianxue Wu, et al.
Publicado: (2021)

Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer
por: Zheng H, et al.
Publicado: (2016)

Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome
por: Zhao Y, et al.
Publicado: (2016)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Peng Su, et al.
Publicado: (2021)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

The therapeutic effect in gliomas of nanobubbles carrying siRNA combined with ultrasound-targeted destruction
por: Cai W, et al.
Publicado: (2018)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Kinome Expansion in the <named-content content-type="genus-species">Fusarium oxysporum</named-content> Species Complex Driven by Accessory Chromosomes
por: Gregory A. DeIulio, et al.
Publicado: (2018)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Hana Kim, et al.
Publicado: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

Manipulating the NF-κB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions
por: Ortega RA, et al.
Publicado: (2016)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different kinds of anticancer drugs
por: Li J, et al.
Publicado: (2016)

Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi Y, et al.
Publicado: (2018)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Miyuki Kitahara, et al.
Publicado: (2021)

Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts
por: Jared R. Thomas, et al.
Publicado: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Asparagine Deprivation Causes a Reversible Inhibition of Human Cytomegalovirus Acute Virus Replication
por: Chen-Hsuin Lee, et al.
Publicado: (2019)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni A, et al.
Publicado: (2016)

Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
por: Mahmoodi Chalbatani G, et al.
Publicado: (2019)

Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy
por: Wang F, et al.
Publicado: (2018)

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
por: Cook MT, et al.
Publicado: (2016)

In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice
por: Shi Q, et al.
Publicado: (2018)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: Luis de la Cruz-Merino, et al.
Publicado: (2021)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)